Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?

COMPASS Pathways believes it has found a viable, mind-altering therapy for treating long-term depression: a synthetic form of psilocybin now in Phase IIb trials which, if successful, could surmount current legal barriers and stigma associated with psychedelic substances, the company’s co-founder and chief innovation officer told Scrip.

A big step towards that goal was achieved this year in a placebo-controlled Phase I study evaluating COMP360 (psilocybin) in healthy volunteers, and which met its endpoints, Ekaterina Malievskaia said....